AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01356043
Drug: S-amlodipine 5mg,Telmisartan 80mg
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: S-amlodipine 5mg and Telmisartan 80mg, Oral, Once a day, for 9 days + Wash out (19 days)
Trial: NCT01356043
Drug: S-amlodipine 5mg
RxNorm normalized name: S-amlodipine
DrugBank: Levamlodipine (DB09237)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-amlodipine 5mg, Oral, Once a day, for 9 days + Wash out(19 days)
Trial: NCT00459290
Drug: mifepristone
RxNorm normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02460692
Drug: dronabinol
RxNorm normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of vaporized cannabis plus either dronabinol or placebo pill
Trial: NCT01811212
Drug: Cabozantinib S-malate
RxNorm normalized name: Cabozantinib S-Malate
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT01458470
Drug: Memantine
RxNorm normalized name: Memantine
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral tablet, 1 BID, 24 weeks
Trial: NCT02390102
Drug: Erythropoietin
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combinaison drug of darboepoetin 0.75µg/Kg + 200mg intravenous iron sucrose
Trial: NCT01237041
Drug: Niacin First
RxNorm normalized name: Niacin
DrugBank: Niacin (DB00627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niacin 500 mg po four times on one of the inpatient days, then placebo on another inpatient day
Trial: NCT01237041
Drug: Dose-Establishing Study 1 Niacin 250mg
RxNorm normalized name: Niacin
DrugBank: Niacin (DB00627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niacin 250 mg po three times at 2 hour intervals on an inpatient day
Trial: NCT01237041
Drug: Dose-Establishing Study 1 Niacin 500mg
RxNorm normalized name: Niacin
DrugBank: Niacin (DB00627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niacin 500 mg po three times at 2 hour intervals on an inpatient day
Trial: NCT01237041
Drug: Dose-Establishing Study 2 Niacin 500mg
RxNorm normalized name: niacin 0.2 MG
DrugBank: Niacin (DB00627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-Label Niacin 500mg four times at 1 hour intervals on an inpatient day
Trial: NCT02776436
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose of prophylactic dexamethasone will be reduced for all patients
Trial: NCT02776436
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: standard prednisone 5 mg bid for patients with prostate cancer
Trial: NCT00043589
Drug: donepezil
RxNorm normalized name: Donepezil
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03592407
Drug: Epacadostat
RxNorm normalized name: epacadostat
DrugBank: Epacadostat (DB11717)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02355938
Drug: Fidaxomicin 200 mg
RxNorm normalized name: fidaxomicin 200 MG
DrugBank: Fidaxomicin (DB08874)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fidaxomicin 200 mg every 12 hours
Trial: NCT02355938
Drug: Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vancomycin 125 mg every 6 hours
Trial: NCT04176419
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25 mg/kg IV bolus before incision, followed by 0.005 mg/kg/minute IV for the remainder of the surgical case excluding the final 30-45 minutes.
Trial: NCT04176419
Drug: Placebo Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25 mg/kg IV bolus before incision, followed by 0.005 mg/kg/minute IV for the remainder of the surgical case excluding the final 30-45 minutes.
Trial: NCT02635802
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: lidocaine 100-400mg,local anesthesia.Critical-Care Observation Tool(CPOT) and Richmond Agitation-Sedation Scale(RASS) are assessed before and after local anesthesia.We should maintain the CPOT≤2 and RASS 0～2.
Trial: NCT02635802
Drug: Remifentanil+Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a loading dose 1.0-2.0μg/kg remifentanil,intravenous injection slowly,time \>1min,then 5μg/kg·h remifentanil pumping immediately if the operation can not be done in 5 minutes.then local anesthesia with lidocaine 100-400mg.Critical-Care Observation Tool(CPOT) and Richmond Agitation-Sedation Scale(RASS) are assessed before and after anesthesia.We should maintain the CPOT≤2 and RASS 0～2,if it is not up to the standard,increasing the pumping rate 0.5μg/kg·h every 2-5min.
Trial: NCT02160301
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PO
Trial: NCT02160301
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV
Trial: NCT02160301
Drug: Oxycodone
RxNorm normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PO
Trial: NCT04176419
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.5 mg/kg IV bolus before incision, followed by infusion of 1.5 mg/kg/hour ideal body weight (max 8 hours) during the case
Trial: NCT04176419
Drug: Placebo Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.5 mg/kg IV bolus before incision, followed by infusion of 1.5 mg/kg/hour ideal body weight (max 8 hours) during the case
Trial: NCT04176419
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 600 mg orally at time of check in to the preoperative unit
Trial: NCT04176419
Drug: Placebo Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 600 mg orally at time of check in to the preoperative unit
Trial: NCT00569439
Drug: NS
RxNorm normalized name: LENS
DrugBank: Scutellaria baicalensis root (DB14364)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline solution at 125 cc/hr
Trial: NCT04597931
Drug: Romosozumab
RxNorm normalized name: ROMOSOZUMAB
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: SC Romosozumab 210 mg/monthly
Trial: NCT02635802
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: midazolam is an adjuvant drug.we should maintain the CPOT≤2 and RASS 0～2,if lidocaine is already used up to 400mg or the pumping rate of remifentanil is already 7.5μg/kg·h,then we should use midazolam 3mg, intravenous injection slowly.
Trial: NCT03764072
Drug: VX-150
RxNorm normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules for oral administration.
Trial: NCT02366637
Drug: PF-03715455
RxNorm normalized name: PF-03715455
DrugBank: PF-03715455 (DB12138)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 680 micrograms BID, Orally inhaled PF-03715455 for 4 weeks
Trial: NCT02944552
Drug: bicyclol tablet 25mg
RxNorm normalized name: alpha-bicyclo[2.2.1]hept-5-en-2-yl-alpha-phenyl-1-piperidinepropanol
DrugBank: Cyclo(his-pro) (DB02414)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the low dose group administrated bicyclol tablet 25mg, one bicyclol blank analog tablet and two polyene phosphatidylcholine blank analog capsules orally, three times daily for 4-8 weeks.
Trial: NCT02944552
Drug: bicyclol tablet 50mg
RxNorm normalized name: alpha-bicyclo[2.2.1]hept-5-en-2-yl-alpha-phenyl-1-piperidinepropanol
DrugBank: Cyclo(his-pro) (DB02414)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the high dose group administrated bicyclol tablet 50mg and two polyene phosphatidylcholine blank analog capsules orally, three times daily for 4-8 weeks.
Trial: NCT05225844
Drug: Camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab ，200mg/㎡，d1，ivgtt，every 21 days as a cycle
Trial: NCT05225844
Drug: Apatinib Mesylate
RxNorm normalized name: mesylate
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib Mesylate，250mg/㎡，po，d1-5 on/d2 off，every 21 days as a cycle
Trial: NCT00809471
Drug: avanafil
RxNorm normalized name: Avanafil
DrugBank: Avanafil (DB06237)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 30 minutes orally prior to initiation of sexual activity
Trial: NCT02288845
Drug: ITI-007
RxNorm normalized name: Arthur Itis
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02355028
Drug: Ranibizumab ophthalmic solution
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: For intravitreal (IVT) injection
Trial: NCT03375502
Drug: Varicella Vaccine
RxNorm normalized name: Varicella vaccine
DrugBank: Varicella zoster vaccine (live/attenuated) (DB10318)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subject will receive investigational product or comparator.
Trial: NCT03697512
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: capsules for oral intake in a dosage of 560 mg (four capsules) daily
Trial: NCT03697512
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Concentrate solution for infusion - intravenous use; Solution for injection - subcutaneous use.
Trial: NCT00410735
Drug: Pranlukast hydrate
RxNorm normalized name: Chloral Hydrate
DrugBank: Pranlukast (DB01411)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: 225 mg BID for 12 weeks
Trial: NCT00820053
Drug: epirubicin and lipiodol
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: using the technology of Seldinger,The drugs (30 mg epirubicin mixed with 5 ml lipiodol) are given via hepatica propria artery.
Trial: NCT03117660
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vitamin A daily X3-4 weeks
Trial: NCT01511029
Drug: Dexpramipexole
RxNorm normalized name: Dexpramipexole
DrugBank: Dexpramipexole (DB15130)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg - Oral Tablets
Trial: NCT01511029
Drug: Dexpramipexole
RxNorm normalized name: Dexpramipexole
DrugBank: Dexpramipexole (DB15130)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg Oral Tablets
Trial: NCT01511029
Drug: Dexpramipexole Placebo
DrugBank: Pramipexole (DB00413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo - Oral Tablet
Trial: NCT01511029
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg - Oral Tablet
Trial: NCT01057810
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5 mg/ml solution, Intravenous, 10 mg/kg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase. Up to 24 weeks in the Induction Phase. Treatment in the Maintenance Phase continues until total treatment period has reached three years,Treatment Stopping Criteria are met, withdrawal of consent, or study closure
Trial: NCT04285255
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ketamine induction and analgesia as opioids free anaesthesia versus opioids analgesia
Trial: NCT04285255
Drug: Dexmedetomidine Injection [Precedex]
RxNorm normalized name: dexmedetomidine Injection [Precedex]
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: alpha 2 agonist with sedative, analgesic effect
Trial: NCT04285255
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: infusion of lidocaine 2%(1mg/kg/h)
Trial: NCT01534026
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Current dose
Trial: NCT04309916
Drug: Tegoprazan
RxNorm normalized name: Tegoprazan
DrugBank: Tegoprazan (DB16690)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegoprazan 50mg tablet
Trial: NCT04309916
Drug: Esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40mg tablet
Trial: NCT00282399
Drug: Subcutaneous Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00347139
Drug: Salmeterol 50mcg
RxNorm normalized name: FLUTICAS 500/SALMETEROL 50MCG INHL DISK
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Salmeterol 50mcg
Trial: NCT01678131
Drug: Vaniprevir 600 mg
RxNorm normalized name: Vaniprevir
DrugBank: Vaniprevir (DB11929)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Vaniprevir capsules, were administered orally, twice per day (BID) to achieve a final daily dose of 600 mg on Days 1 through 6; and a single dose of 600 mg, orally, on Day 7.
Trial: NCT03456856
Drug: Ivabradine
RxNorm normalized name: Ivabradine
DrugBank: Ivabradine (DB09083)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Film-coated tablets taken orally with food twice a day. Tablets supplied in strengths of 5.0 mg and 7.5 mg. 5.0 tablets were split into equal halves for dosages of 2.5 mg.
Trial: NCT01559025
Drug: Vildagliptin
RxNorm normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Vildagliptin ( Galvus 50mg twice day) during one year
Trial: NCT00000825
Drug: Aldesleukin
RxNorm normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00857896
Drug: Fesoterodine
RxNorm normalized name: Fesoterodine
DrugBank: Fesoterodine (DB06702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 mg once daily for Weeks 1-4 and 8 mg once daily for Weeks 5-8
Trial: NCT01680536
Drug: maraviroc
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04478721
Drug: Temocillin
RxNorm normalized name: temocillin
DrugBank: Temocillin (DB12343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention of experimental arm will be Intravenous administration of temocillin.
Trial: NCT04478721
Drug: Meropenem
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The intervention of comparator arm will be intravenous administration of meropenem.
Trial: NCT04512196
Drug: Superoxidized Water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Super-oxidized solution contains hypochlorous acid (HOCl) which exhibits bactericidal activity. These reactive species create an imbalanced osmotic gradient which damages the cell membrane integrity of single celled organisms, and subsequently denaturing its lipid and protein content. Multicellular organisms including host tissue are not susceptible to such changes in osmolarity hence spared from damage.
Trial: NCT00687843
Drug: Tegafur-gimeracil-oteracil potassium (TS-1)
RxNorm normalized name: tegafur
DrugBank: Oteracil (DB03209)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: 80 mg/m2, PO from day 1 to day 28 of each 42 day cycle. Number of Cycles: 8
Trial: NCT03461952
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 240mg
Trial: NCT03461952
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1mg/kg
Trial: NCT01931475
Drug: Duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02794792
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral
Trial: NCT00806663
Drug: sunitinib added to FOLFIRI
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: sunitinib 37 mg once daily (4 weeks on/2 weeks off)
Trial: NCT00596817
Drug: Vortioxetine (Lu AA21004)
RxNorm normalized name: Vortioxétine
DrugBank: Vortioxetine (DB09068)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: encapsulated tablets, daily, orally
Trial: NCT01654718
Drug: Pantoprazole
RxNorm normalized name: Pantoprazole
DrugBank: Pantoprazole (DB00213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pantoprazole 40mg Delayed release tablets (Test Product)
Trial: NCT01654718
Drug: Pantoprazole
RxNorm normalized name: Pantoprazole
DrugBank: Pantoprazole (DB00213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Protonix® Delayed Release 40 mg tablets (Reference product)
Trial: NCT00155272
Drug: Thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03219840
Drug: Cetylpyridinium Chloride (CPC) 0.09% + Xylitol chewing gum
DrugBank: Cetylpyridinium (DB11073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated.
Trial: NCT03219840
Drug: Xylitol only chewing gum
RxNorm normalized name: Xylitol
DrugBank: Xylitol (DB11195)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated.
Trial: NCT01678131
Drug: Vaniprevir 300 mg
RxNorm normalized name: Vaniprevir
DrugBank: Vaniprevir (DB11929)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Vaniprevir capsules were administered orally, twice per day to achieve a final daily dose of 300 mg on Days 1 through 6; and a single dose of 300 mg, orally, on Day 7.
Trial: NCT01175096
Drug: RAD001 (everolimus, Afinitor®)
RxNorm normalized name: everolimus 10 MG [Afinitor]
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: RAD001 will be provided by Novartis to the study sites. RAD001 is formulated as tablets of 5 mg strength, blister-packed under aluminum foil in units of 30 tablets. The study site will dispense an adequate supply of RAD001 to the patient for self-administration at home.~2 x 5 mg (=10 mg) RAD001 p.o., once daily, at the same time each day, One treatment cycle consists of 28 days.
Trial: NCT06253364
Drug: PD-1 monoclonal antibody and lenvatinib
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adjuvant PD-1 group: Patient receives first adjuvant PD-1 monoclonal antibody 2-4 weeks postoperatively, 200mg IV over 21 days for 9 cycles.~Adjuvant PD-1 plus Lenvatinib group: Patient receives first adjuvant PD-1 monoclonal antibody 2-4 weeks postoperatively, 200 mg IV 21 days for 9 cycles; lenvatinib is initiated orally 2-4 weeks postoperatively for 6 months.
Trial: NCT00443079
Drug: IdB 1016 (Siliphos)
RxNorm normalized name: Eliphos
DrugBank: Calcium acetate (DB00258)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 pill 3 times daily x 6 weeks
Trial: NCT03152084
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The study consists of a 2-week, open label, dapagliflozin (10mg) treatment period.
Trial: NCT03356080
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine,iv,0.1-0.2mg/kg, Day1-Day3 per week,up to 3 weeks
Trial: NCT03356080
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cytarabine, iv,15mg/m2 q12h, Day1-Day10
Trial: NCT03356080
Drug: All-transretinoic acid
RxNorm normalized name: (all-Z)-4,7,10,13,16-docosapentaenoic acid
DrugBank: Osbond acid (DB14088)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All-transretinoic acid, 45mg/d Day4-Day6;15mg/d Day7-Day20
Trial: NCT03356080
Drug: G-CSF
RxNorm normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: G-CSF 300ug,sc,Day 0 until CR is achieved
Trial: NCT00546065
Drug: esomeprazole treatment
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: concomitant esomeprazole treatment
Trial: NCT01054092
Drug: ipragliflozin
RxNorm normalized name: ipragliflozin
DrugBank: Ipragliflozin (DB11698)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: oral
Trial: NCT01901601
Drug: Retrobulbar Block or General Anesthesia
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00716014
Drug: TD101
RxNorm normalized name: TD101
DrugBank: TD101 (DB06596)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TD101 is injection into a callus on the bottom of one of the patient's feet
Trial: NCT00716014
Drug: Normal saline (placebo)
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A normal saline solution (placebo) is injected into one of the patient's feet.
Trial: NCT00691912
Drug: Myocet / Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 20 mg/m² Myocet® as 30-minutes infusion on day 1,8,15 80 mg/m² Paclitaxel as 60-minutes infusion on day 1,8,15 q21d
Trial: NCT04292912
Drug: GSK2798745
RxNorm normalized name: GSK2798745
DrugBank: GSK2798745 (DB16033)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2798745 will be administered.
Trial: NCT03106363
Drug: Alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single oral administration of an alcoholic beverage mixed in a 1:3 ratio of alcohol to tonic water to obtain a target blood alcohol content of 0.08mg%.